Last reviewed · How we verify
CNS 7056
CNS 7056 is a kappa opioid receptor antagonist.
CNS 7056 is a kappa opioid receptor antagonist. Used for Chronic pain.
At a glance
| Generic name | CNS 7056 |
|---|---|
| Also known as | remimazolam |
| Sponsor | Paion UK Ltd. |
| Drug class | Opioid receptor antagonist |
| Target | Kappa opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
CNS 7056 works by blocking the kappa opioid receptor, which is involved in pain modulation and other physiological processes. This action is thought to contribute to its analgesic effects.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Vomiting
- Headache
Key clinical trials
- Effect of Remimazolam and Propofol on Postoperative Delirium (NA)
- Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery (NA)
- Actualities in Procedural Sedation: Remimazolam (PHASE4)
- Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia
- Ketamine for Veterans With Parkinson's Disease (PHASE2)
- Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients (PHASE2)
- Optimal Insertion Time During Remimazolam-Remifentanil Anesthesia for Painless Gastroscopy (NA)
- ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CNS 7056 CI brief — competitive landscape report
- CNS 7056 updates RSS · CI watch RSS
- Paion UK Ltd. portfolio CI